Details for Patent: 11,590,246
✉ Email this page to a colleague
Which drugs does patent 11,590,246 protect, and when does it expire?
Patent 11,590,246 protects ELUCIREM and is included in one NDA.
This patent has forty-four patent family members in twenty-seven countries.
Summary for Patent: 11,590,246
| Title: | Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process |
| Abstract: | The present invention relates to a complex of formula (II) constituted of at least 90% of a diastereoisomeric excess comprising a mixture of isomers II-RRR and II-SSS of formulae:The present invention also relates to a process for preparing and purifying said complex of formula (II), and also to a composition comprising said complex. |
| Inventor(s): | Soizic le Greneur, Alain CHÉNEDÉ, Martine Cerf, Myriam Petta, Emmanuelle Marais, Bruno François, Caroline Robic, Stéphanie LOUGUET |
| Assignee: | Guerbet SA |
| Application Number: | US17/423,638 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 11,590,246
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Guerbet | ELUCIREM | gadopiclenol | SOLUTION;INTRAVENOUS | 216986-001 | Sep 21, 2022 | RX | Yes | Yes | 11,590,246 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Guerbet | ELUCIREM | gadopiclenol | SOLUTION;INTRAVENOUS | 216986-002 | Sep 21, 2022 | RX | Yes | Yes | 11,590,246 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Guerbet | ELUCIREM | gadopiclenol | SOLUTION;INTRAVENOUS | 216986-003 | Sep 21, 2022 | RX | Yes | Yes | 11,590,246 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Guerbet | ELUCIREM | gadopiclenol | SOLUTION;INTRAVENOUS | 216986-004 | Sep 21, 2022 | RX | Yes | Yes | 11,590,246 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Guerbet | ELUCIREM | gadopiclenol | SOLUTION;INTRAVENOUS | 216986-005 | Sep 21, 2022 | RX | Yes | Yes | 11,590,246 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,590,246
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 117835 | ⤷ Start Trial | |||
| Australia | 2020208794 | ⤷ Start Trial | |||
| Brazil | 112021014006 | ⤷ Start Trial | |||
| Canada | 3126268 | ⤷ Start Trial | |||
| Chile | 2021001868 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
